Sfoglia per AUTORE
TISEO M
Collezione AOU Novara

  

Items : 9

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

2022
AOU Novara

Banna GL; Tiseo M; Cortinovis DL; Facchinetti F; Aerts JGJV; Baldessari C; Giusti R; Bria E; Grossi F; Berardi R; Morabito A; Catino A; Genova C; Mazzoni F; Gelibter A; Rastelli F; Macerelli M; Chiari R; Gori S; Mansueto G; Citarella F; Cantini L; Rijavec E; Bertolini F; Cappuzzo F; De Toma A; Friedlaender A; Metro G; Pensieri MV; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico / Clin Transl Oncol. 2020 Mar;22(3):294-301. doi: 10.1007/s12094-019-02222-8. Epub 2019 Oct 19.
2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Novello S; Di Maio M; Tiseo M; Galetta D; Bria E; Rossi G; Tabbò F; Cortinovis D; Rizzo P; Delmonte A; Bareggi C; Del Conte A; Sergi C; Casartelli C; Gregorc V; Graziano P; Rossi A; Maiello E; Scotti V; Martelli O; Borra G; Riccardi F; Osman G; Cappuzzo F; Cecere F; Pilotto S; Ghilardi L; Bordi P; Gobbini E; et alii...

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2020 Feb;140:71-79. doi: 10.1016/j.lungcan.2019.12.006. Epub 2019 Dec 16.
2020
AOU San Luigi di Orbassano
AOU Novara

Novello S; Rossi A; Ferrari S; Zullo A; Vattemi E; Pagano M; Carta A; Martelli O; Gelibter A; Pino MS; Cecere F; Berardi R; Tonini G; Migliorino MR; Sergi C; Galetta D; Scotti V; Nonnis D; Verderame F; Borra G; Piovano PL; Del Conte A; Romano GD; Finocchiaro G; Ceresoli GL; Cortinovis D; Vitiello F; Barbieri F; Tiseo M; et alii...

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. in Translational cancer research / Transl Cancer Res. 2019 Jan;8(Suppl 1):S16-S22. doi: 10.21037/tcr.2018.12.32.
2019
AOU San Luigi di Orbassano
AOU Novara

Romano G; Roca E; Morabito A; Montrone M; Minotti V; Migliorino MR; Melotti B; Mazzanti P; Martelli O; Malorgio F; Mancuso G; Landi L; Irtelli L; Gregorc V; Gilli M; Franchina T; Del Conte A; D'Argento E; Cusmai A; Danesi R; Costanzo R; Cortinovis D; Carta A; Bulotta A; Buffoni L; Borra G; Bettini A; Bianco R; Barbieri V; et alii...

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2019 Dec 15;25(24):7312-7319. doi: 10.1158/1078-0432.CCR-19-0994. Epub 2019 Aug 15.
2019
AOU Novara

Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F;

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14.
2016
AOU Novara

Cappuzzo F; Morabito A; Normanno N; Bidoli P; Del Conte A; Giannetta L; Montanino A; Mazzoni F; Buosi R; Burgio MA; Cerea G; Chiari R; Cortinovis D; Finocchiaro G; Foltran L; Migliorino MR; Tiseo M; Ferrari S; De Marinis F;